S&P 500   4,256.83 (+1.18%)
DOW   33,637.82 (+0.90%)
QQQ   328.47 (+1.35%)
AAPL   171.48 (+1.77%)
MSFT   289.69 (+0.93%)
META   179.80 (+1.30%)
GOOGL   120.47 (+1.37%)
AMZN   141.55 (+0.65%)
TSLA   885.84 (+3.02%)
NVDA   185.34 (+3.30%)
NIO   21.02 (+0.96%)
BABA   94.43 (-0.46%)
AMD   100.66 (+2.59%)
MU   65.29 (+4.77%)
T   18.19 (+0.83%)
CGC   3.27 (+3.81%)
GE   79.19 (+0.37%)
F   16.08 (+1.58%)
DIS   120.82 (+2.66%)
AMC   25.53 (+0.27%)
PYPL   100.72 (+1.62%)
PFE   50.04 (+3.62%)
NFLX   246.72 (+1.66%)
S&P 500   4,256.83 (+1.18%)
DOW   33,637.82 (+0.90%)
QQQ   328.47 (+1.35%)
AAPL   171.48 (+1.77%)
MSFT   289.69 (+0.93%)
META   179.80 (+1.30%)
GOOGL   120.47 (+1.37%)
AMZN   141.55 (+0.65%)
TSLA   885.84 (+3.02%)
NVDA   185.34 (+3.30%)
NIO   21.02 (+0.96%)
BABA   94.43 (-0.46%)
AMD   100.66 (+2.59%)
MU   65.29 (+4.77%)
T   18.19 (+0.83%)
CGC   3.27 (+3.81%)
GE   79.19 (+0.37%)
F   16.08 (+1.58%)
DIS   120.82 (+2.66%)
AMC   25.53 (+0.27%)
PYPL   100.72 (+1.62%)
PFE   50.04 (+3.62%)
NFLX   246.72 (+1.66%)
S&P 500   4,256.83 (+1.18%)
DOW   33,637.82 (+0.90%)
QQQ   328.47 (+1.35%)
AAPL   171.48 (+1.77%)
MSFT   289.69 (+0.93%)
META   179.80 (+1.30%)
GOOGL   120.47 (+1.37%)
AMZN   141.55 (+0.65%)
TSLA   885.84 (+3.02%)
NVDA   185.34 (+3.30%)
NIO   21.02 (+0.96%)
BABA   94.43 (-0.46%)
AMD   100.66 (+2.59%)
MU   65.29 (+4.77%)
T   18.19 (+0.83%)
CGC   3.27 (+3.81%)
GE   79.19 (+0.37%)
F   16.08 (+1.58%)
DIS   120.82 (+2.66%)
AMC   25.53 (+0.27%)
PYPL   100.72 (+1.62%)
PFE   50.04 (+3.62%)
NFLX   246.72 (+1.66%)
S&P 500   4,256.83 (+1.18%)
DOW   33,637.82 (+0.90%)
QQQ   328.47 (+1.35%)
AAPL   171.48 (+1.77%)
MSFT   289.69 (+0.93%)
META   179.80 (+1.30%)
GOOGL   120.47 (+1.37%)
AMZN   141.55 (+0.65%)
TSLA   885.84 (+3.02%)
NVDA   185.34 (+3.30%)
NIO   21.02 (+0.96%)
BABA   94.43 (-0.46%)
AMD   100.66 (+2.59%)
MU   65.29 (+4.77%)
T   18.19 (+0.83%)
CGC   3.27 (+3.81%)
GE   79.19 (+0.37%)
F   16.08 (+1.58%)
DIS   120.82 (+2.66%)
AMC   25.53 (+0.27%)
PYPL   100.72 (+1.62%)
PFE   50.04 (+3.62%)
NFLX   246.72 (+1.66%)
NASDAQ:GMDA

Gamida Cell - GMDA Stock Forecast, Price & News

$3.18
-0.21 (-6.19%)
(As of 08/12/2022 01:38 PM ET)
Add
Compare
Today's Range
$2.98
$3.48
50-Day Range
$1.53
$3.39
52-Week Range
$1.48
$5.91
Volume
36,548 shs
Average Volume
544,156 shs
Market Capitalization
$188.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.83

Gamida Cell MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
344.8% Upside
$13.83 Price Target
Short Interest
Bearish
5.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Gamida Cell in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.22) to ($1.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

716th out of 1,117 stocks

Biological Products, Except Diagnostic Industry

111th out of 175 stocks

GMDA stock logo

About Gamida Cell (NASDAQ:GMDA) Stock

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Gamida Cell Price Performance

Shares of GMDA traded up $0.75 during trading hours on Thursday, hitting $3.39. 5,690,513 shares of the company were exchanged, compared to its average volume of 753,424. The company has a market capitalization of $200.69 million, a PE ratio of -2.37 and a beta of 1.72. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.55 and a quick ratio of 3.55. The firm has a fifty day simple moving average of $1.94 and a 200-day simple moving average of $2.78. Gamida Cell has a one year low of $1.48 and a one year high of $5.91.

Gamida Cell (NASDAQ:GMDA - Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.34) earnings per share for the quarter, hitting the consensus estimate of ($0.34). During the same period in the prior year, the business earned ($0.34) EPS. As a group, sell-side analysts predict that Gamida Cell will post -1.22 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GMDA. JMP Securities reiterated a "buy" rating and set a $17.00 price target on shares of Gamida Cell in a research report on Thursday, June 2nd. Piper Sandler lowered their price target on Gamida Cell from $13.00 to $6.00 in a research report on Tuesday, May 10th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Gamida Cell currently has a consensus rating of "Buy" and an average target price of $13.83.

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Stock News Headlines

Gamida Cell Q1 2022 Earnings Preview
See More Headlines
Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Company Calendar

Last Earnings
11/15/2021
Today
8/12/2022
Next Earnings (Confirmed)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMDA
Fax
N/A
Employees
166
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.83
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+335.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-89,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.74 per share

Miscellaneous

Free Float
57,661,000
Market Cap
$188.26 million
Optionable
Not Optionable
Beta
1.72

Key Executives

  • Dr. Julian Adams Ph.D. (Age 67)
    CEO & Director
    Comp: $707k
  • Mr. Shai Lankry C.P.A. (Age 46)
    M.B.A., Chief Financial Officer
    Comp: $564k
  • Ms. Michele Ilene Korfin M.B.A. (Age 50)
    R.Ph., Chief Operating & Chief Commercial Officer
    Comp: $510k
  • Dr. Ronit Simantov M.D. (Age 57)
    Chief Medical & Chief Scientific Officer
    Comp: $581k
  • Dr. Jas Uppal (Age 54)
    Chief Regulatory & Quality Officer
    Comp: $476k
  • Mr. Joshua F. Patterson (Age 46)
    Gen. Counsel & Chief Compliance Officer
  • Mr. Paul Nee
    VP of Marketing
  • Mr. Naftali Brikashvili CPA
    Sr. VP Fin. & Operations
  • Dr. Tracey Lodie Ph.D. (Age 52)
    Scientific Advisor & Consultant
  • Mr. Vladimir Melnikov
    Sr. VP of Global Operations & Manufacturing













GMDA Stock - Frequently Asked Questions

Should I buy or sell Gamida Cell stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GMDA shares.
View GMDA analyst ratings
or view top-rated stocks.

What is Gamida Cell's stock price forecast for 2022?

6 Wall Street research analysts have issued 12 month target prices for Gamida Cell's shares. Their GMDA share price forecasts range from $6.00 to $22.00. On average, they predict the company's share price to reach $13.83 in the next year. This suggests a possible upside of 308.1% from the stock's current price.
View analysts price targets for GMDA
or view top-rated stocks among Wall Street analysts.

How have GMDA shares performed in 2022?

Gamida Cell's stock was trading at $2.54 on January 1st, 2022. Since then, GMDA stock has increased by 33.5% and is now trading at $3.39.
View the best growth stocks for 2022 here
.

When is Gamida Cell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our GMDA earnings forecast
.

How can I listen to Gamida Cell's earnings call?

Gamida Cell will be holding an earnings conference call on Monday, August 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd. (NASDAQ:GMDA) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.15. During the same quarter in the previous year, the firm posted ($0.30) EPS.

What other stocks do shareholders of Gamida Cell own?

When did Gamida Cell IPO?

(GMDA) raised $50 million in an initial public offering on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Who are Gamida Cell's major shareholders?

Gamida Cell's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (1.21%), JPMorgan Chase & Co. (0.89%), Walleye Capital LLC (0.30%) and OLD National Bancorp IN (0.05%).

How do I buy shares of Gamida Cell?

Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $3.39.

How much money does Gamida Cell make?

Gamida Cell (NASDAQ:GMDA) has a market capitalization of $200.69 million. The company earns $-89,790,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does Gamida Cell have?

The company employs 166 workers across the globe.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for the company is www.gamida-cell.com. The company can be reached via phone at (722) 659-5666 or via email at irpr@gamida-cell.com.

This page (NASDAQ:GMDA) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.